


## SMU-L11

Cat. No.:	HY-157793
Molecular Formula:	C <sub>19</sub> H <sub>24</sub> N <sub>4</sub> O
Molecular Weight:	324.42
Target:	NF-κB; Toll-like Receptor (TLR); MAPKAPK2 (MK2)
Pathway:	NF-κB; Immunology/Inflammation; MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	SMU-L11 is a specific TLR7 agonist (EC <sub>50</sub> =0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4 <sup>+</sup> T and CD8 <sup>+</sup> T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases <sup>[1]</sup> .
IC <sub>50</sub> & Target	TLR7 0.024 μM (EC50)

### REFERENCES

[1]. Ou J, et al. Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma. J Med Chem. 2024 Feb 16.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA